Receptor TrK
Os inibidores dos receptores Trk têm como alvo as quinases receptoras da tropomiosina (Trk), uma família de tirosina quinases receptoras que desempenham um papel significativo no desenvolvimento e função do sistema nervoso. Os receptores Trk estão envolvidos na sinalização de neurotrofinas, essencial para a sobrevivência, diferenciação e crescimento dos neurônios. A desregulação da sinalização Trk está associada a distúrbios neurológicos e certos tipos de câncer. Na CymitQuimica, oferecemos inibidores dos receptores Trk para apoiar sua pesquisa em neurobiologia, oncologia e doenças neurodegenerativas.
Foram encontrados 56 produtos de "Receptor TrK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Paltimatrectinib
CAS:Paltimatrectinib (PBI-200) is a tyrosine kinase inhibitor with anticancer activity, and is used in the study of bladder, breast, and colorectal cancers.Fórmula:C20H15F5N6Pureza:99.96%Cor e Forma:SolidPeso molecular:434.37TRK-IN-24
CAS:TRK-IN-24 (compound 10g) is a selective inhibitor of Trk receptors, effectively targeting TRKA, TRKC, and mutant forms TRKA G595R, TRKA G667C, and TRKA F589L,Fórmula:C39H45N7O3Pureza:98%Cor e Forma:SolidPeso molecular:659.82Type II TRK inhibitor 1
CAS:Type II TRK Inhibitor 1 is a potent inhibitor targeting multiple tropomyosin receptor kinase (TRK) fusion protein variants as well as the wild type.Fórmula:C35H33F3N8O3Pureza:98%Cor e Forma:SolidPeso molecular:670.68AZ-23
CAS:AZ-23 is an inhibitor of ATP-competitive and Trk kinase A/B/C.Fórmula:C17H19ClFN7OPureza:99.4%Cor e Forma:SolidPeso molecular:391.83TrkA-IN-9
CAS:TrkA-IN-9 (VMD-928) is an orally active and selective inhibitor of tropomyosin receptor kinase A (TrkA). It disrupts downstream signaling pathways activated by nerve growth factor (NGF) binding to TrkA, thereby inhibiting cell proliferation and invasion, and promoting cancer cell death. TrkA-IN-9 shows potential for research in various cancers, including prostate cancer, thymic carcinoma, mesothelioma, head and neck squamous cell carcinoma, lung cancer, ovarian cancer, and hepatocellular carcinoma.Fórmula:C31H32N4O4Cor e Forma:SolidPeso molecular:524.61TrkC-IN-1
CAS:TrkC-IN-1 (Compound 6c) is an inhibitor of TrkC, with IC50 values of 3.3-7.1 and 7.3-10.2 μΜ for EBC-1 and HT-29 cells, respectively. This compound shows potential for research in the field of cancer therapeutics.Fórmula:C28H20BrN5O2Cor e Forma:SolidPeso molecular:538.395BNN-20
CAS:BNN-20 is a synthetic micro-neurotrophic factor that mimics Brain-Derived Neurotrophic Factor (BDNF) and exhibits region-specific neuroprotective and neurogenesis-promoting effects. It is applicable in research related to Parkinson's disease.Fórmula:C20H30O2Cor e Forma:SolidPeso molecular:302.45TRK-IN-28
CAS:TRK-IN-28 (compound 30f) functions as a TRK inhibitor, displaying potencies with IC 50 values of 0.55 nM for TRK WT, 25.1 nM for TRK G595R, and 5.4 nM for TRK G667C. Another TRK inhibitor, TRK-IN-2, exhibits antiproliferative effects with IC 50 values against multiple cell lines: 9.5 nM for Ba/F3-ETV6-TRKA WT, 3.7 nM for Ba/F3-ETV6-TRKB WT, 205.0 nM for Ba/F3-LMNA-TRK G595R, and 48.3 nM for Ba/F3-LMNA-TRKA G667C [1].Fórmula:C27H25F2N7Cor e Forma:SolidPeso molecular:485.53TRK-IN-26
CAS:TRK-IN-26 (compound 12), a TRK inhibitor, holds potential for use in cancer research [1].Fórmula:C30H22F2N6O4Cor e Forma:SolidPeso molecular:568.53TrkA-IN-7
CAS:TrkA-IN-7 (Compound 4) is an inhibitor of tropomyosin receptor kinase A (TrkA), with a Kd value of 40 μM.Fórmula:C16H13N3O3Cor e Forma:SolidPeso molecular:295.293PF-06273340
CAS:PF-06273340 是一种口服具有活力的、具有选择性的外周限制性Trk 泛抑制剂。Fórmula:C23H22ClN7O3Pureza:98% - 98.00%Cor e Forma:SolidPeso molecular:479.92TrkA-IN-8
CAS:TrkA-IN-8 (Compound 2) is a TrkA inhibitor with a Kd value of 3.3 µM. RTKs-IN-1 demonstrates a concentration-dependent inhibitory effect on the proliferation of lung cancer cell lines and holds potential for research in non-small cell lung cancer.Fórmula:C20H16N4Cor e Forma:SolidPeso molecular:312.368NMS-P626
CAS:NMS-P626 functions as an inhibitor targeting TRKA, TRKB, and TRKC, exhibiting IC 50 values of 8 nM, 7 nM, and 3 nM respectively. It effectively suppresses KM12 cell growth by inhibiting the phosphorylation of TPM3-TRKA and the subsequent downstream signaling, demonstrating an IC 50 of 19 nM specifically for KM12 cells. This compound is applicable in the study of colorectal cancer.Fórmula:C28H35F2N7O4SCor e Forma:SolidPeso molecular:603.68ONO-7579
CAS:ONO-7579, an orally active TRKA inhibitor, effectively suppresses tumor growth by inhibiting TRKA phosphorylation. In KM12 colorectal cancer cells, it exhibits an EC 50 of 17.6 ng/g, indicating that a concentration of 17.6 ng per gram of tumor tissue reduces the activity of phosphorylated TRKA by 50%. This compound is utilized in cancer research.Fórmula:C24H18ClF3N6O4SCor e Forma:SolidPeso molecular:578.95Trk-IN-4
CAS:Trk-IN-4 (PF-6683324) is a potent pan-Trk inhibitor and antinociceptive. It is also a selective type II PTK6 inhibitor antitumor.Fórmula:C24H23F4N5O4Pureza:98.13%Cor e Forma:SolidPeso molecular:521.46TrkB-IN-1
CAS:TrkB-IN-1 is a potent, orally active agonist of the TrkB receptor, with favorable pharmacokinetic (PK) properties.
Fórmula:C19H16N2O6Pureza:98%Cor e Forma:SolidPeso molecular:368.34
